Physician profile
Barry Katz
NPI 1427035120
$12,271.09
in general payments reported to CMS, 2019-2025
44 companies · $2,350 in 2025
The $2,350 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,708 · 2020: $967 · 2021: $1,408 · 2022: $1,639 · 2023: $1,692 · 2024: $2,507 · 2025: $2,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,509 · Education: $39.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,508.54 |
| Education | $39.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,371.77 | 2019-2025 | |
| Janssen Biotech, INC. | $1,370.76 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Phathom Pharmaceuticals, INC. | $719.26 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $653.18 | 2021-2025 | Sucraid, Sucraid |
| Janssen Scientific Affairs, LLC | $633.55 | 2019-2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $593.43 | 2019-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $568.09 | 2022-2025 | Dupixent |
| Pfizer INC. | $515.02 | 2019-2025 | |
| Genzyme Corporation | $393.51 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $365.35 | 2019-2022 | |
| Celgene Corporation | $328.48 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $267.55 | 2019-2025 | Ocaliva |
| Amgen INC. | $249.18 | 2020-2023 | Amjevita, Avsola |
| Madrigal Pharmaceuticals | $239.43 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $226.16 | 2019-2025 | Livdelzi |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.